Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Carfilzomib Induction with Lenalidomide and Clarithromycin Consolidation and Lenalidomide Maintenance (CarBiRD) for Multiple Myeloma (MM)

Peter A. Forsberg, MD, Adriana C Rossi, MD, MSc, Roger N Pearse, MD PhD, Arthur Perry, PA, Karen Pekle, NP, David Jayabalan, BSMS, MSc, Scott Ely, MD MPH, Morton Coleman, MD, John N. Allan, MD, Ruben Niesvizky, MD, Tomer Mark, MD MSc

Blood (2016) 128 (22): 4518.

https://doi.org/10.1182/blood.V128.22.4518.4518

Published: 2016

Journal Articles

Sequencing of Proteasome Inhibitors in Patients with Multiple Myeloma

Benjamin Diamond, MD, Adriana C Rossi, MD, MSc, Roger N Pearse, MD PhD, David Jayabalan, BSMS, MSc, Arthur Perry, PA, Karen Pekle, NP, Tomer Mark, MD MSc, Ruben Niesvizky, MD

Blood (2016) 128 (22): 4522.

https://doi.org/10.1182/blood.V128.22.4522.4522

Published: 2016

Journal Articles

High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma

Tomer M Mark, MD MSc, Sujitha Yadlapati, MBBS, Lyubov Neglyad, Jennifer Bourke, RN, David Jayabalan, BSMS, MSc, Adriana C Rossi, MD, Roger N Pearse, MD PhD, Arthur Perry, PA, Karen Pekle, NP, Kathleen Pogonowski, RN, Linda Tegnestam, RN, Xiangao Huang, PhD, Maurizio Di Liberto, PhD, Scott Ely, MD MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2015) 126 (23): 4258.

https://doi.org/10.1182/blood.V126.23.4258.4258

Published: 2015

Journal Articles

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide and Bortezomib

Tomer M Mark, MD MSc, Angelique Boyer, Sujitha Yadlapati, MBBS, Adriana C Rossi, MD, Roger N Pearse, MD PhD, Karen Pekle, NP, Arthur Perry, PA, Kathleen Pogonowski, RN, Ekta Aneja, MD, Linda Tegnestam, RN, David Jayabalan, BSMS, MSc, Scott Ely, MD MPH, Morton Coleman, MD, Xiangao Huang, PhD, Maurizio Di Liberto, PhD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2015) 126 (23): 4232.

https://doi.org/10.1182/blood.V126.23.4232.4232

Published: 2015

Journal Articles

Rising Plasma Cell Proliferation By Ki67/CD138 Ratio at Relapse Is a Marker of High Risk Disease in Multiple Myeloma

Peter A. Forsberg, MD, Tomer M Mark, MD MSc, Sujitha Yadlapati, MBBS, Adriana C Rossi, MD MHS, Roger N Pearse, MD PhD, Karen Pekle, NP, Arthur Perry, PA, Morton Coleman, MD, David Jayabalan, BSMS, MSc, Ruben Niesvizky, MD, Scott Ely, MD MPH

Blood (2015) 126 (23): 2991.

https://doi.org/10.1182/blood.V126.23.2991.2991

Published: 2015

Journal Articles

The Ki67/CD138 Ratio Independently Predicts Overall Survival in the Upfront Treatment of Newly Diagnosed Multiple Myeloma

Tomer M Mark, MD MSc, Peter Forsberg, MD, Ihsane Ouansafi, MD, Adriana C Rossi, MD, Roger N Pearse, MD PhD, Karen Pekle, NP, Arthur Perry, PA, Morton Coleman, MD, David Jayabalan, BSMS, MSc, Ruben Niesvizky, MD, Scott A Ely, MD MPH

Blood (2014) 124 (21): 2016.

https://doi.org/10.1182/blood.V124.21.2016.2016

Published: 2014

Journal Articles

Effect of Renal and Hepatic Function on Pomalidomide Dose in Patients with Relapsed/Refractory Multiple Myeloma

Adriana C Rossi, MD, Ekta Aneja, MBBS, Angelique Boyer, David Jayabalan, BSMS, MSc, Tomer M Mark, MD MSc, Roger Pearse, MD PhD, Karen Pekle, NP, Arthur Perry, PA, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2014) 124 (21): 4754.

https://doi.org/10.1182/blood.V124.21.4754.4754

Published: 2014

Journal Articles

Car-Bird [Carfilzomib, Clarithromycin(Biaxin ® ), Lenalidomide/(Revlimid ® ), Dexamethasone) for Newly-Diagnosed Multiple Myeloma

Tomer M Mark, MD MSc, Abbe Schickner, BA, John N. Allan, MD, Adriana C Rossi, MD, Roger Pearse, MD PhD, Linda Tegnestam, RN, Karen Pekle, NP, Arthur Perry, PA, Kathleen Pognowski, RN, David Jayabalan, BSMS, MSc, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2014) 124 (21): 4761.

https://doi.org/10.1182/blood.V124.21.4761.4761

Published: 2014

NARROW

Carfilzomib Induction with Lenalidomide and Clarithromycin Consolidation and Lenalidomide Maintenance (CarBiRD) for Multiple Myeloma (MM)

Sequencing of Proteasome Inhibitors in Patients with Multiple Myeloma

High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide and Bortezomib

Rising Plasma Cell Proliferation By Ki67/CD138 Ratio at Relapse Is a Marker of High Risk Disease in Multiple Myeloma

The Ki67/CD138 Ratio Independently Predicts Overall Survival in the Upfront Treatment of Newly Diagnosed Multiple Myeloma

Effect of Renal and Hepatic Function on Pomalidomide Dose in Patients with Relapsed/Refractory Multiple Myeloma

Car-Bird [Carfilzomib, Clarithromycin(Biaxin ® ), Lenalidomide/(Revlimid ® ), Dexamethasone) for Newly-Diagnosed Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only